CNS Drug Discoveries

Summary

Among the key developments addressed in the new 750-page November 2006 edition:

Neurodegenerative Disorders

• What are the leading Alzheimer's and Parkinson's disease brands?
• What disease-modifying agents are emerging?
• How are companies managing the patent exposure within their neurodegenerative portfolios?

Multiple Sclerosis

• How is Tysabri (Elan) performing following its temporary suspension?
• What is the latest clinical data on Mylinax (Serono/IVAX) and Neurelan (Elan/Acorda)?
• What other products are in the pipeline?

Attention Deficit Hyperactivity Disorder (ADHD)

• What products are in Phase II/III and when will they reach the market?
• How is the launch of Shire's MethyPatch going?
• To what degree will the approval of NRP104 (Shire/New River) change the market dynamics?

Depression

• What impact have generics had on market dynamics?
• How have safety concerns influenced prescribing habits?
• What Phase IV data has driven sales?

Sleep Disorders

• Will Neurocrine's indiplon reach the market?
• How does gaboxadol (Merck & Co/ Lundbeck) compare to its peers?
• What is sanofi-aventis' pipeline looking like?

Schizophrenia - new in this edition!

• How has the safety of atypical antipsychotics affected the market?
• Who is the market leader and why?
• What pipeline products are in development and how do they compare with the competition?

For each therapy area the report provides

Comprehensive Overview

• Patient statistics:
• Prevalence, diagnosed and treatment rates
• Patient populations in the US, Europe and Japan

Growth drivers:
Risk factors (genetics, age, sex), medical guidelines, unmet clinical need and off-label use in other CNS disorders

Growth dampeners:
Safety issues, label changes, impact of generics, reimbursement and ethical issues

An overview of the value of the CNS market:

• Global sales
• Sales growth to 2012

A review of the major players based on market share/sales

Current treatments:

• Competitor analysis of leading brands and companies
• Patent exposure
• Where and why there is still an unmet clinical need?
• Sales forecasts by product 2005-2012

Drugs in Phase II/III development:

• Focus on new classes of drugs and companies involved
• Sales forecasts by product year of launch to 2012

Competitor ratio analysis:
Analysis of drugs and companies within each sector based on drugs analysed in the report and using 5 point criteria for success evaluation

Winners & losers:
Identify the winners and losers within each sector based on competitor analysis, current pipeline products and market conditions

About the Author
Dr Cheryl Barton is a highly regarded independent consultant with over 15 years research and business analysis experience. Following her senior research positions in academia and seven years with Merck, in which she was responsible for research projects ranging from Alzheimer's disease to schizophrenia, Dr Barton joined Dutch investment bank ABN Amro NV as a senior equity analyst. At ABN Amro NV she was lead analyst on major pharmaceutical companies such as Roche and Sanofi-Synthlabo, and assessed the potential impact of new drug development on European Stocks.

In 2002, Dr Barton established a consulting business to provide independent, tailor-made, pharmaceutical thematic research to investment houses and pharmaceutical companies. The research combines independent scientific analysis with patient-based models to forecast the potential sales growth of key drugs in clinical development.

CNS Drug Discoveries:

• what the future holds
• Understand the prospects for this US$67.8 billion market.
• Revised edition provides critical development update.
• Unique market share and sales forecasts by product to 2012.
• A comprehensive examination of 6 major CNS therapy areas.
• Detailed competitor analysis of current and upcoming products.

Contents

• Executive Summary
  • Figure 1. Global CNS Market (US$68.7 billion)
  • Competitor Ratio Analysis - Drugs
  • CNS Drugs Analysed for Launch by 2012 - Therapeutic Category
  • Competitor Ratio Analysis - Companies
  • CNS Drugs Analysed for Launch by 2012 -Major Pharma Companies
  • Pharmaceutical Companies and products analysis in this report
  • CNS Drugs Analysed for Launch by 2012 -Speciality Pharma & Biotech Companies
  • Biotechnology and Specialty Pharma Companies and products analysis in this report
  • About the Author
• Attention Deficit Hyperactivity Disorder
• Executive Summary
  • THE FACTS
  • What is ADHD and why are we interested in it?
  • Symptoms of ADHD subtype
  • Rates of Co-morbid Conditions among Children with ADHD
• Patient Statistics
  • Incidence, diagnosis rates and treatment; now and in the future
• Patient Model
  • The addressable ADHD market will have show 6.5% CAGR over the period 2005-2012
  • Summary of patient population forecasts 2005A-2012E
  • DRUG GROWTH DRIVERS
  • DRUG GROWTH RISKS/DAMPENERS
• Global Adhd Market
  • Global CNS Market (US$68.7 billion)
• Global Sales Split
  • Global sales split (2005A)
  • US market
  • ADHD US drugs sales split (2005A)
  • European market
  • ADHD European drugs sales split (2005A)
  • Japanese market
  • The major players
  • Market share of ADHD players by sales (Dec 2005A)
  • Players and Products in 2005 & 2006
  • Players and Products in 2012
  • Market share of ADHD players by sales (Dec 2012E)
• Current Treatments
  • Leading Brands
  • Comparison of leading ADHD drugs
  • Current Products Patent Exposure
• Analysis Of Leading Brands
  • Stimulants
  • Non-Stimulant
• Stimulants
  • Adderall and Adderall XR (Shire)
  • Concerta and Concerta XL (Johnson & Johnson)
  • Competitor Ratio Analysis
  • Daytrana (Shire)
  • Focalin/Focalin XR (Novartis)
  • Ritalin/Ritalin LA (Novartis)
  • Metadate ER/Equasym and Metadate CD/Equasym XL (UCB)
  • NON STIMULANT
  • Strattera (Eli Lilly)
• Global Sales Forecasts Of Current Treatments 2005 - 2012
  • Sales Forecasts of Current Leading ADHD Drugs
  • Model assumptions
  • NEW DRUGS IN R&D
  • Drugs in Development to Treat ADHD
• Analysis Of Phase Iii Drugs
  • New Drugs in Phase III Development to Treat ADHD
  • Non-Stimulant
  • Stimulant
  • Connexyn (Shire)
  • p-value of ADHD-RS Efficacy of SPD503 versus placebo in Phase III trials
  • Changing in ADHD Rating Score Connexyn (Study 301) and Strattera (Study 3468)
  • NRP104 (Shire)
  • SPD465 (Shire)
• Global Sales Forecasts Of Phase Iii Adhd Drugs 2006 - 2012
  • Sales Forecasts of Phase III Developmental ADHD Drugs
  • Model assumptions
• Analysis Of Phase Ii Drugs
  • New Drugs in Early Clinical Development to Treat ADHD
  • NS2359 (GSK, NeuroSearch)
  • CX717 (Cortex Pharmaceuticals)
  • PRX-00023
  • SGS742
  • Abilify
• Global Sales Forecasts Of Phase Ii Adhd Drugs 2006 - 2012
  • Sales Forecasts of Phase 2 Developmental ADHD Drugs
  • Model assumptions
• Competitor Ratio Analysis
  • CR Analysis of ADHD Agents Approved by 2012 - Based on Drug Class
• Competitor Ratio Analysis - Companies
  • CR Analysis of ADHD Agents Approved by 2012 - Based on Company
• Winners & Losers
  • Summary of Key Companies and Drugs in the ADHD Market by 2012
  • Winners
  • Losers
• Discontinuation Of Drugs
  • ADHD drugs discontinued from clinical development
  • ADHD APPENDIX 1
  • Assessment of ADHD Criteria
  • ADHD APPENDIX 2
  • Phase transition probability
  • Probability of launch
  • ADHD APPENDIX 3
  • Patient Model
  • Summary of US ADHD Patient Population Forecasts
  • Summary of Europe (Top 5) ADHD Patient Population Forecasts
  • Summary of Japan ADHD Patient Population Forecasts
  • ADHD APPENDIX 4
  • Global ADHD Drugs Sales 2005-20012
  • Global ADHD Drug Sales 2005A-2012E (US$ million)
  • ADHD APPENDIX 5
  • Competitor Ratio Analysis Criteria
  • Key ADHD Drugs on the Market by 2012
  • ADHD GLOSSARY
  • ADHD REFERENCES
• Acronyms
• Depression
• Executive Summary
  • THE FACTS
  • What is depression and why are we interested in it?
• Patient Statistics
  • Incidence, diagnosis rates and treatment; now and in the future
• Patient Model
  • Summary of patient population forecasts in seven major markets (2005A-2012E)
  • Model assumptions
  • DRUG GROWTH DRIVERS
  • DRUG GROWTH RISKS/DAMPENERS
• Global Antidepressant Market
  • Global CNS Market (US$68.7 billion)
• Global Sales Split
  • Global sales by region (2005A)
  • US market
  • Antidepressant US drugs sales by (2005A)
  • European market
  • European Antidepressant sales by (2005A)
  • ROW/Japanese market
  • The Major Players Products in 2005 & 2006
  • Market share of Antidepressant players by sales (Dec 2005A)
  • The Major Players and Products in 2012
  • Market share of Antidepressant Players by sales (Dec 2012E)
• Current Treatments
  • Leading Brands
  • Comparison of leading antidepressant drugs
  • Patent Exposure of Current Products
  • Patent Exposure of Leading Antidepressant Brands
• Analysis Of Leading Brands
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Lexapro/Cipralex (Forest/Lundbeck)
  • Prozac (Eli Lilly)
  • Zoloft (Pfizer)
  • Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)
  • Cymbalta (Eli Lilly)
  • Effexor (Wyeth)
  • Noradrenaline and Dopamine Reuptake Inhibitors (NDRIs)
  • Wellbutrin (GlaxoSmithKline)
• Global Sales Forecasts Of Current Treatments 2005 - 2012
  • Sales Forecasts of Current Leading Antidepressant Drugs
  • Model assumptions
  • NEW DRUGS IN R&D
  • Drugs in Development to Treat Depression and Anxiety Related Disorders
• Analysis Of Phase Iii Drugs
  • New Drugs in Phase III Development to Treat Depression and Anxiety
  • Phase III drugs
  • Other Phase III drugs of interest
• Insomnia
• Executive Summary
  • THE FACTS
  • What is insomnia and why are we interested in it?
• Patient Statistics
  • Summary of insomnia patient population in top 5 European countries
• Patient Model
  • The addressable insomnia market will have a CAGR 2005-2012 = 5.9%
  • Patient population and sub-types of insomnia
  • Summary of patient population (for top seven countries) forecasts
  • DRUG GROWTH DRIVERS
  • DRUG GROWTH RISKS/DAMPNERS
• Global Insomnia Market
  • Global CNS Market (US$68.7 billion)
• Global Sales Split
  • US market
  • Insomnia US drugs sales split (2005A)
  • European market
  • Insomnia European drugs sales split (2005A)
  • Japanese market
  • Insomnia Japanese drugs sales split (2005A)
  • The major players
  • Market share of insomnia players by sales (Dec 2005A)
  • Players and Products in 2005
  • Players and Products in 2012
  • Market share of insomnia players by sales (Dec 2012E)
• Current Treatments
  • Leading Brands
  • Comparison of Leading Brands
  • Current Products Patent Exposure
  • Patent exposure of leading brands
• Analysis Of Leading Brands
  • GABA-A Receptor Agonists
  • Melatonin Receptor Agonist
  • GABA-A Receptor Agonists
  • Ambien/Stilnox/Myslee and Ambien CR (sanofi-aventis)
  • Lunesta (Sepracor)
  • Sonata (King Pharmaceuticals)
  • Melatonin Receptor Agonist
  • Rozerem (Takeda)
  • Distribution of ML-1 and ML-2 receptors
• Global Sales Forecasts Of Current Treatments 2005 - 2012
  • Sales Forecasts of Current Leading Insomnia Drugs (US$ million)
  • Model assumptions
  • NEW DRUGS IN R&D
  • Drugs in Development to Treat Insomnia
• Analysis Of Phase Iii Drugs
  • Drugs in Phase III Development to Treat Insomnia
  • GABA-A Receptor Agonists
  • Histamine Receptor Antagonist
  • 5-HT2A Receptor Antagonist
  • Melatonin Receptor Agonist
  • indiplon (Neurocrine Biosciences)
  • gaboxadol (Lundbeck)
  • Silenor (Somaxon)
  • Eplivanserin (sanofi-aventis)
  • Effect of eplivanserin on sleep parameters in Phase IIb trial
  • VEC-162 (Vanda Pharmaceuticals)
  • Efficacy of VEC-162 in transient insomnia trials
• Global Sales Forecasts Of Phase Iii Insomnia Drugs 2006 - 2012
  • Sales Forecasts of Phase III Developmental Insomnia Drugs
  • Model assumptions
• Analysis Of Phase Ii Drugs
  • New Drugs in Early Clinical Development to Treat Insomnia
  • 5-HT2A Receptor Antagonists
  • GABA-A Receptor Modulator
  • Melatonin Analogue
  • 5-HT2A RECEPTOR ANTAGONISTS
  • M100907 (sanofi-aventis)
  • Pruvanserin (Eli Lilly)
  • GABA-A MODULATORS
  • NG2-73 (Neurogen)
• Melatonin Analogue
  • PD-6735 (Phase II Discovery)
• Global Sales Forecasts Of Phase Ii Insomnia Drugs 2006 - 2012
  • Sales Forecasts of Insomnia Drugs in Phase III
  • Model assumptions
  • CR Analysis of Insomnia Agents Approved by 2012 - Based on Drug Class
• Competitor Ratio Analysis - Companies
  • CR Analysis of Insomnia Agents Approved by 2012 - Based on Company
• Winners & Losers
  • Summary of Key Companies and Drugs in the Insomnia Market by 2012
  • Winners
  • Losers
• Discontinuation Of Drugs
• Insomnia Appendix 1
  • Analysis of clinical trial data
• Insomnia Appendix 2
  • Phase transition probability
  • Probability of launch
• Insomnia Appendix 3
  • Patient Model
  • Summary of US Insomnia Patient Population Forecasts
  • Summary of Europe (Top 5) Insomnia Patient Population Forecasts
  • Summary of Japan Insomnia Patient Population Forecasts
• Insomnia Appendix 4
  • Global Drug Sales 2005-2012 (US$ million)
• Insomnia Appendix 5
  • Competitor Ratio Analysis Criteria
  • Key insomnia drugs due to be launched by 2012
• Insomnia Glossary
• Insomnia References
  • Acronyms
  • Multiple Sclerosis
• Executive Summary
  • THE FACTS
  • What is MS and why are we interested in it?
• Patient Statistics
  • Incidence, diagnosis rates and treatment; now and in the future
  • MS categories
  • Types of MS
• Patient Model
  • The treatable MS patient population will have a CAGR 2005-2012 = 4.6%
  • Summary of patient population forecasts
  • DRUG GROWTH DRIVERS
  • DRUG GROWTH RISKS/DAMPENERS
• Global Ms Market
  • Global CNS Market (US$68.7 billion)
• Global Sales Split
  • Global sales split (2005A)
  • US market
  • MS US drugs sales split (2005A)
  • European market
  • MS European drugs sales split (2005A)
  • Japanese market
  • The major players
  • Market share of MS players by sales (Dec 2005A)
  • Players and Products in 2005 & 2006
  • Players and products in 2012
• Current Treatments
  • Leading Brands
  • Comparison of Leading MS Agents
  • Current Products Patent Exposure
  • Patent Exposure of Leading Brands
• Analysis Of Leading Brands
  • Disease-modifying agents
  • Disease-modifying agents
  • Avonex (Biogen Idec/Genzyme)
  • Betaferon/Betaseron (Berlex/Schering AG)
  • Copaxone (Teva)
  • Rebif (Serono)
  • Tysabri
  • Novantrone (Serono)
• Global Sales Forecasts Of Current Treatments 2005-2012
  • Sales Forecasts of Current Leading MS Drugs
  • Model assumptions
  • NEW DRUGS IN R&D
  • Drugs in Development to Treat MS
• Analysis Of Phase Iii Drugs
  • New Drugs in Phase III Development to Treat MS
  • Disease-modifying agents
  • MS Symptoms
  • Campath (Genzyme/Schering AG)
  • FTY720 (Novartis)
  • Laquinimod (Teva/Active Biotech)
  • MBP8298 (BioMS)
  • Mylinax (Serono/Ivax)
  • Rituxan (Genentech/Biogen Idec/Roche/Chugai/Zenyaju Kogyo)
  • Teriflunomide (sanofi-aventis)
  • MS Symptoms
  • Neurelan (Elan/Acorda)
  • Trial MS-F202: Timed 25-foot walk response rate of MS patients treated with Fampridine SR
• Global Sales Forecasts Of Phase Iii Ms Drugs 2006-2012
  • Sales Forecasts of Phase III Developmental MS Drugs
  • Model assumptions
• Analysis Of Phase Ii Drugs
  • New Drugs in Early Clinical Development to Treat MS
  • Disease-modifying agents
  • Vaccines
  • Disease-modifying agents
  • ABT-874 (Abbott)
  • ATL1102 (Antisense/ISIS pharmaceuticals)
  • BG-12 (Biogen Idec)
  • Daclizumab (Biogen Idec/BioPharma)
  • SB-683699 (GlaxoSmithKline/Tanabe Seiyaku)
  • Vaccines
  • NeuroVax (TIRC)
  • Tovaxin (Opexa Therapeutics)
  • Other Interesting Phase II Drugs
• Global Sales Forecasts Of Phase Ii Ms Drugs 2006 - 2012
  • Sales Forecasts of Phase II Developmental MS Drugs
  • Model assumptions
• Competitor Ratio Analysis - Products
  • CR Analysis of MS Agents Approved by 2012 - Based on Drug Class
• Competitor Ratio Analysis - Companies
  • CR Analysis of MS Agents Approved by 2012 - Based on Company
• Winners & Losers
  • Summary of Key Companies and Drugs in the MS Market by 2012
  • Winners
  • Losers
• Discontinuation Of Drugs
  • MS Drugs Discontinued from Clinical Development
  • MS APPENDIX 1
  • Clinical diagnostic test for MS
  • MS APPENDIX 2
  • Expanded Disability Status Scale (EDSS)
  • MS APPENDIX 3
  • Phase transition probability
  • Probability of launch
  • MS APPENDIX 4
  • Patient Model
  • Summary of US MS Patient Population Forecasts
  • Summary of Europe (Tope 5) MS Patient Population Forecasts
  • Summary of Japan MS Patient Population Forecasts
  • MS APPENDIX 5
  • Global MS Drugs Sales 2005-20012
  • Global MS Drug Sales 2005A-2012E
  • Ms APPENDIX 6
  • Competitor Ratio Analysis Criteria
  • Key MS Drugs on the Market by 2012
  • MS GLOSSARY
  • MS REFERENCES
• Acronymns
• Neurodegeneration
• Executive Summary
  • THE FACTS
  • What is neurodegeneration and why are we interested in it?
• Patient Statistics
  • Incidence, diagnosis rates and treatment; now and in the future
• Patient Model
  • The addressable AD and PD patient population will grow by 2% per annum
  • Summary of AD patient population forecasts 2005A-2012E
  • Summary of PD patient population forecasts 2005A-2012E
  • DRUG GROWTH DRIVERS
  • DRUG GROWTH RISKS/DAMPENERS
• Global Ad/Pd Market
  • Global CNS Market (US$68.7 billion)
• Global Sales Split
  • AD and PD Global sales split (2005A)
  • AD Global sales split (2005A)
  • PD Global sales split (2005A)
  • US market
  • AD US drugs sales split (2005A)
  • PD US drugs sales split (2005A)
  • European market
  • AD European drugs sales split (2005A)
  • PD European drugs sales split (2005A)
  • Japan
  • Split between AD and PD in Japan (2005A)
  • The major players
  • Market Share of AD players by sales (Dec 2005A)
  • Market Share of PD players by sales (Dec 2005A)
  • Players and Products in 2012
  • Market Share of AD players by sales (Dec 2012E)
  • Players and Products in 2012
  • Market Share of PD players by sales (Dec 2012E)
• Current Ad Treatments
• Current Pd Treatments
  • Leading Brands
  • Comparison of leading AD drugs
  • Comparison of leading PD drug classes
  • Patent Exposure of Current Products
  • Patent Exposure of Leading AD Brands
  • Patent Exposure of Leading PD Brands
• Analysis Of Leading Brands
  • AD Agents
  • PD Agents
  • Acetylcholine Esterase (AChE) Inhibitors
  • Aricept (Eisai)
  • Exelon (Novartis)
  • Razadyne (Johnson & Johnson/Shire)
  • NMDA Antagonist
  • Namenda/Ebixa (Forest/Lundbeck)
  • Dopamine Agonists
  • Apokyn (Britannia/Vernalis)
  • Neupro (Schwarz Pharma)
  • Sifrol/Mirapex/Mirapexin (Boehringer Ingelheim)
  • Requip (GlaxoSmithKline)
  • Monoaminoxidase (MAO) Inhibitors
  • Azilect (Lundbeck/Teva)
  • Catechol-O-Methyltransferase (COMT) Inhibitors
  • Comtan/Comtess & Stalevo (Novartis)
• Global Sales Forecasts Of Current Treatments 2005 - 2012
  • Sales Forecasts of Current Leading AD Drugs
  • Sales Forecasts of Current Leading PD Drugs 2005 - 2012
  • Model assumptions
  • NEW DRUGS IN R&D
  • Drugs in Development to Treat AD and PD
• Analysis Of Phase Iii Drugs
  • New Drugs in Phase III Development to Treat AD and PD
  • AD Agents
  • PD Agents
  • AD Agents
  • Alzhemed (Neurochem)
  • Flurizan (Myriad Genetics)
  • Phenserine (Axonyx)
  • Xaliproden (sanofi-aventis)
  • Parkinson's Disease
  • E2007 (Eisai)
  • Istradefylline (Kyowa Hakko)
  • Safinamide (Newron)
  • SLV308 (Solvay)
  • Spheramine (Schering AG/Titan)
• Global Sales Forecasts Of Phase Iii Ad And Pd Drugs 2006 - 2012
  • Sales Forecasts of Phase III Developmental AD and PD Drugs
  • Model assumptions
• Analysis Of Phase Ii Drugs
  • New Drugs in Early Clinical Development to Treat AD and PD
  • AD Agents
  • PD Agents
  • AD agents
  • Bapineuzumab (Wyeth/Elan)
  • Other promising Phase II drugs
  • CX717 (Cortex Pharmaceuticals)
  • EVT 101 (Evotec)
  • Ketasyn (Accera)
  • MEM 1003 (Memory Pharmaceuticals)
  • PBT2 (Prana)
  • SGS-742 (Saegis Pharmaceuticals)
  • PD drugs
  • SR 57667 (sanofi-aventis)
  • Talampanel (IVAX)
  • VR040 (Vectura)
• Competitor Ratio Analysis Products/Drugs
  • CR Analysis of AD Agents Approved by 2012 - Based on Drug Class
  • CR Analysis of PD Agents Approved by 2012 - Based on Drug Class
• Competitor Ratio Analysis - Companies
  • CR Analysis of AD and PD Agents Approved by 2012 - Based on Company
• Winners & Losers
  • Summary of Key Companies and Drugs in the AD and PD Market by 2012
• Discontinuation Of Drugs
  • AD and PD drugs discontinued from clinical development
• Neurodegenerative Appendix 1
  • Phase transition probability
  • Probability of launch
• Neurodegenerative Appendix 2
  • AD Patient Model
  • Summary of AD Patient Population Forecasts
• Neurodegenerative Appendix 3
  • PD Patient Model
  • Summary of PD Patient Population Forecasts
• Neurodegenerative Appendix 4
  • Global AD Drugs Sales 2005-2012
  • Global AD Drug Sales 2005A-2012E
• Neurodegenerative Appendix 5
  • Global PD Drugs Sales 2005-2012
  • Global PD Drug Sales 2005A-2012E
• Neurodegenerative Appendix 6
  • Competitor Ratio Analysis Criteria
  • Key AD & PD Drugs on the Market by 2012
• Neurodegenerative Glossary
• Neurodegenerative References
• Acronyms
• Schizophrenia
• Executive Summary
  • THE FACTS
  • What is schizophrenia and why are we interested in it?
  • Symptoms associated with schizophrenia
  • Schematic depicting mood swings in bipolar disorder
• Patient Statistics
  • Incidence, diagnosis rates and treatment; now and in the future
• Patient Model
  • Summary of patient population forecasts 2005A-2012E
  • DRUG GROWTH DRIVERS
  • DRUG GROWTH RISKS/DAMPENERS
• Global Schizophrenia Market
  • Global CNS Market (US$68.7 billion)
• Global Sales Split
  • Global sales split (2005A)
  • Prescription usage split (2005A)
  • The major players
  • Market share of antipsychotic players by sales (Dec 2005A)
  • Market share of antipsychotic players by sales (Dec 2006E)
  • Players and Products in 2005 & 2006
  • Players and Products in 2012
  • Market share of antipsychotic players by sales (Dec 2012E)
• Current Treatments
  • Leading Brands
  • Comparison of leading antipsychotic drugs
  • Current Products Patent Exposure
  • Patent Exposure of Leading Antipsychotic Brands
• Analysis Of Leading Brands
  • Atypical antipsychotics
  • Other Agents
• Atypical Antipsychotics
  • Abilify (Bristol-Myers Squibb/Otsuka)
  • Geodon/Zeldox (Pfizer)
  • Risperdal (Johnson & Johnson)
  • Seroquel (AstraZeneca)
  • Zyprexa (Eli Lilly)
  • Other atypical antipsychotics:
  • Serdolect (Lundbeck)
  • Lullan
  • Clozaril/Leponex (Novartis)
  • Solian (sanofi-aventis)
• Global Sales Forecasts Of Current Treatments 2005 - 2012
  • Sales Forecasts of Current Leading Antipsychotics
  • Model assumptions
  • NEW DRUGS IN R&D
  • Drugs in Development to Treat Schizophrenia and Bipolar Disorder
• Analysis Of Phase Iii Drugs
  • Drugs in Phase III Development to Treat Schizophrenia and Bipolar Disorder
  • D/5-HT receptor antagonists
  • D/5-HT receptor antagonists
  • Asenapine (Pfizer/Organon)
  • Bifeprunox (Wyeth/Solvay/Lundbeck)
  • Blonanserin (Dainippon Sumitomo)
  • Clinical Efficacy of Blonanserin
  • Iloperidone (Vanda Pharmaceutical)
  • Safety Profile of Iloperidone vs. Approved Antipsychotics
  • Paliperidone (Johnson & Johnson)
• Global Sales Forecasts Of Phase Iii Schizophrenia Drugs 2006 - 2012
  • Sales Forecasts of Phase III Developmental Antipsychotic Drugs
  • Model assumptions
• Analysis Of Phase Ii Drugs
  • New Drugs in Early Clinical Development to Treat Schizophrenia/Bipolar Disorder
  • Lurasidone (Dainippon Sumitomo/Merck & Co.)
  • Ocaperidone (Neuro3d)
  • SGS518 (Eli Lilly/Saegis Pharmaceuticals)
  • Talnetant (GlaxoSmithKline)
  • Talnetant Efficacy and Safety Profile
  • Talnetant Cognitive Effects
  • ABT-089 (Abbott)
  • ORG 24448 (Akzo Nobel/Cortex Pharmaceuticals)
  • Vabicaserin (Wyeth)
• Global Sales Forecasts Of Phase Ii Antipsychotic Drugs 2005-2012
  • Sales Forecasts of Phase II Developmental Antipsychotic Drugs
  • Model assumptions
• Competitor Ratio Analysis
  • CR Analysis of Antipsychotic Agents Approved by 2012 - Based on Drug Class
• Competitor Ratio Analysis - Companies
  • CR Analysis of Antipsychotics Approved by 2012 - Based on Company
• Winners & Losers
  • Summary of Key Companies and Drugs in the Antipsychotic Market by 2012
  • Winners
  • Losers
• Discontinuation Of Drugs
  • Antipsychotic Drugs Discontinued from Clinical Development
• Schizophrenia Appendix 1
  • Assessment of antipsychotic efficacy in schizophrenia
  • Assessment of antipsychotic efficacy in bipolar disorder
• Schizophrenia Appendix 2
  • Phase transition probability
  • Probability of launch
• Schizophrenia Appendix 3
  • Patient Model
  • Summary of US Schizophrenia Patient Population Forecasts
  • Summary of European (Top 5) Schizophrenia Patient Population Forecasts
  • Summary of Japanese Schizophrenia Patient Population Forecasts
• Schizophrenia Appendix 4
  • Global Antipsychotic Drug Sales 2005A-2012E
• Schizophrenia Appendix 5
  • Competitor Ratio Analysis Criteria
  • Key Antipsychotic Drugs on the Market by 2012
• Schizophrenia Glossary
• Schizophrenia References
• Acronyms